Log In
BCIQ
Print this Print this
 

halofuginone (HT-100)

  Manage Alerts
Collapse Summary General Information
Company Akashi Therapeutics Inc.
DescriptionOral delayed-release formulation of halofuginone, a collagen type I (COL1) synthesis inhibitor
Molecular Target Glutamyl-prolyl-tRNA synthetase (EPRS)
Mechanism of ActionCollagen type I (COL1) synthesis inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I/II
Standard IndicationMuscular dystrophy
Indication DetailsTreat Duchenne muscular dystrophy (DMD)
Regulatory Designation U.S. - Fast Track (Treat Duchenne muscular dystrophy (DMD));
U.S. - Orphan Drug (Treat Duchenne muscular dystrophy (DMD));
EU - Orphan Drug (Treat Duchenne muscular dystrophy (DMD))
PartnerGruenenthal Group

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$1.0M

$1.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/08/2016

Undisclosed

Undisclosed

Undisclosed

01/09/2012

$1.0M

$1.0M

0

Get a free BioCentury trial today